John P. Schmid
CIK 1478916 · Chief Financial Officer · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANAB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6005 HIDDEN VALLEY ROAD, SUITE 110
CARLSBAD, CA 92011
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) Delisted | Director | 6,000 | $16.39 | $98.3K | $96.0K | 1 | 2026-08-10 |
| ANAB | Director | 37,652 | $48.77 | $1.84M | -$1.16M | 18 | 2026-06-17 |
| TRAX | Director | 37,652 | $43.48 | $1.64M | $0 | 4 | 2026-06-17 |
| DSGN | Director | 57,639 | $10.34 | $596.0K | $99.7K | 7 | 2026-06-11 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 7 | 2025-01-08 |
| XERS | Director | 138,359 | $10.21 | $1.41M | $50.1K | 12 | 2024-08-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 6 | 2021-03-19 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Financial Officer | 0 | — | — | $0 | 2 | 2015-05-06 |
| Trius Therapeutics Inc (TSRX) Delisted | Chief Financial Officer | 107,639 | — | — | -$85.0K | 23 | 2013-03-11 |
Recent Filings · Page 2 of 9
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-08 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2025-12-23 | ANAB | Other (J) | −11,068 | -$564.5K | EDGAR |
| 2025-08-11 | BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | Exer (M) | +30,000 | $0 | EDGAR |
| 2025-06-17 | ANAB | Exer (M) | +6,030 | $0 | EDGAR |
| 2025-06-12 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2025-03-27 | ANAB | Other (J) | +11,068 | $201.2K | EDGAR |
| 2025-01-15 | ANAB | Exer (M) | +42,337 | $275.0K | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −58,950 | $0 | EDGAR |
| 2025-01-07 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2024-08-13 | XERS | Buy (P) | +4,515 | $10.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.